Novartis advances on receiving USFDA nod for heart failure drug

10 Jul 2015 Evaluate

Novartis India is currently trading at Rs. 829.00, up by 29.90 points or 3.74% from its previous closing of Rs. 799.10 on the BSE.

The scrip opened at Rs. 820.00 and has touched a high and low of Rs. 844.00 and Rs. 815.60 respectively. So far 1,11,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 5 has touched a 52 week high of Rs. 869.60 on 11-Jun-2015 and a 52 week low of Rs. 539.95 on 27-Mar-2015.

Last one week high and low of the scrip stood at Rs. 844.00 and Rs. 760.00 respectively. The current market cap of the company is Rs. 2,652.00 crore.

The promoters holding in the company stood at 75.00% while Institutions and Non-Institutions held 2.38% and 22.62% respectively.

Novartis has received nod from the US health regulator for its heart failure treatment tablets - LCZ696 - and the company plans to launch the medicine in India. It will benefit many patients afflicted with heart failure.

The company plans to launch LCZ696 (sacubitril/valsartan) tablets under the brand name 'Entresto' in the US market. The tablets-LCZ696 will reduce risk of death from cardiovascular causes by 20 percent and will offer to patients a much greater opportunity to live longer and stay out of hospital.

Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.


Novartis Share Price

800.45 10.50 (1.33%)
11-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Redington 279.75
Adani Enterprises 2276.65
Amrapali Industries 15.09
Rashi Peripheral 335.05
PDS 352.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×